XTX Topco’s BioLineRX BLRX Stock Holding History

XTX Topco’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,941	Closed	-$25.3K	–	4165
2026 Q1	$25.3K	Buy	+10,941	New	+$30.7K	﹤0.01%	3492
2024 Q4	–	Sell	-1,103	Closed	-$23.7K	–	2316
2024 Q3	$23.7K	Buy	+1,103	New	+$30.3K	﹤0.01%	1810
2024 Q2	–	Sell	-787	Closed	-$35.3K	–	1888
2024 Q1	$35.3K	Buy	+787	New	+$39.5K	﹤0.01%	1530
2023 Q4	–	Sell	-584	Closed	-$42.5K	–	1619
2023 Q3	$42.5K	Buy	+584	New	+$39.2K	0.01%	1296

Other funds holding BLRX

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCV

Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

XTX Topco's BLRX Position: Q2 2026 in Review

XTX Topco sold out of BioLineRX (BLRX) in Q2 2026, closing a stake of 10,941 shares — an estimated $25.3K sold.

XTX Topco first reported a position in BLRX in Q3 2023 and held it in 4 quarters. The position peaked at $42.5K in Q3 2023. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

XTX Topco reported no remaining BioLineRX position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 10,941 BioLineRX shares in Q2 2026, an estimated $25.3K.
XTX Topco first reported a position in BioLineRX in Q3 2023 and held it in 4 quarters.
XTX Topco's BioLineRX position peaked at $42.5K in Q3 2023.
14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.